Clinical Infectious Diseases · 2021 · 22 citations · 9 references
Public AffairsNonprofit ManagementPharmaceutical PolicyAntimicrobial ResistanceFundraisingPhilanthropyAntibiotic ResistanceAntimicrobial Resistance ControlAntimicrobial Resistance GovernanceAntimicrobial Resistance PolicyNonprofit Health Care FinancePharmaceutical FinancingAntibiotic Access EquityAntibiotic RegulationAntimicrobial Resistance FinancingEquitable Access To AntimicrobialsGlobal Action Plan On Antimicrobial ResistanceGovernment Health Program OversightGovernment Project OversightIncentives For Antibiotic Development
Antibiotics underpin modern medicine and are critical for pandemic preparedness. Push funding has revitalized the preclinical antimicrobial resistance (AMR) pipeline and government funding via CARB-X and BARDA, as well as private sector-led investment via the AMR Action Fund, will help several new antibiotics obtain regulatory approval. Nevertheless, revenues generated by new antibiotics are not considered sufficiently profitable by commercial developers to address unmet need. The question remains: Who could viably fund development and secure global equitable access for new antibiotics? Public health need should be the primary driver for antibiotic development. Improved prioritization and government oversight by funders who allocate public resources are a needed first step. In this framework, nonprofit research and development organizations, with support from public funders, and unconstrained by commercial profitability requirements are well positioned to work with public and private actors to viably provide new antibiotics to all in need.
9
Katherine H. Luepke, Katie J. Suda, Helen W. Boucher et al. · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 2016 · 348 citations · Full text
Dzintars Gotham, Lorenzo Moja, Maarten van der Heijden et al. · Health Policy · 2020 · 70 citations · Full text